An Open Label, Dose Escalation Followed by Dose Expansion, Safety and Tolerability Trial of CAN04, a Fully Humanized Monoclonal Antibody Against IL1RAP, in Subjects With Solid Malignant Tumors

Trial Profile

An Open Label, Dose Escalation Followed by Dose Expansion, Safety and Tolerability Trial of CAN04, a Fully Humanized Monoclonal Antibody Against IL1RAP, in Subjects With Solid Malignant Tumors

Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 06 Aug 2018

At a glance

  • Drugs Nidanilimab (Primary)
  • Indications Adenocarcinoma; Advanced breast cancer; Colorectal cancer; Non-small cell lung cancer; Pancreatic cancer
  • Focus Adverse reactions; First in man
  • Acronyms CANFOUR
  • Sponsors Cantargia
  • Most Recent Events

    • 06 Aug 2018 Planned number of patients changed to 100.
    • 13 Oct 2017 According to a Cantargia media release, the first patient in this trial has received three cycles of treatment with CAN04. The first patient has formally completed the safety evaluation period according to the clinical protocol. The results from the first part of this trial are expected during summer 2018.
    • 31 Aug 2017 Status changed from not yet recruiting to recruiting.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top